PET image quality of a LAFOV PET/CT scanner compared to a standard SAFOV PET/CT scanner in patients with metabolic tissue activity, neuroendocrine tumors and other somatostatin receptor-positive tumors, prostate cancer and liver cancer Evaluation of PET/CT image quality in patients with high tissue activity and common cancers, including hormone-related tumors, prostate cancer, and liver cancer
Conditions
Interventions
The Omni Legend 128 is an advanced PET/CT system developed by GE HealthCare, featuring an extended axial field-of-view (LAFOV) of 128 cm. Equipped with fully digital detectors and deep crystals (30 mm
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Aged 18 years or above Referred for a diagnostic PET/CT examination with [18F]FDG, [68Ga]DOTATATE, 68Ga]PSMA, or Y90-microspheres Capable to provide written informed consent
Exclusion criteria
Exclusion criteria: Diagnostic CT with administration of a contrast agent required Claustrophobia affecting the patient to the extent that lying in the scanner for any additional period of time is not feasible. Inability to remain still for the duration of the PET/CT examinations Known or suspected pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary study parameter(s) Difference in image quality between LAFOV PET/CT images and reference PET/CT will be assessed by comparing rated image quality scores (Likert scale, 1 – 5) using a Wilcoxon signed-rank test. Patients with missing outcome values will be excluded. | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference in lesion conspicuity and image noise between LAFOV PET/CT images and reference PET/CT will be assessed by comparing rated visual lesion conspicuity scores (Likert scale, 1 – 5) and image noise scores (Likert scale, 1 – 5) using Wilcoxon signed-rank tests. Difference in quantitative PET tracer uptake values (SUVmax, SUVmean and SUV ratio’s) between LAFOV PET/CT and reference PET/CT in normal organs and lesions will be assessed using paired samples t-tests or Wilcoxon signed-rank tests as appropriate, depending on the distribution of the data as determined by a Shapiro-Wilk test. Difference in signal-to-noise ratio in the liver between LAFOV PET/CT and reference PET/CT will be assessed using a paired samples t-test or a Wilcoxon signed-rank test as appropriate, depending on the distribution of the data as determined by a Shapiro-Wilk test.The baseline characteristics (e.g., age, length, BMI, etc.) of all included patients will be analysed using descriptive statistics (e.g., mean and standard deviation, etc.). | — |
Countries
Netherlands
Contacts
Public ContactF.A. Verburg
Erasmus MC, Universitair Medisch Centrum Rotterdam
Outcome results
None listed